HALO,BDX Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI VB XBI VBK VXF MDY IWP XMHQ IBB

Index	-	P/E	17.57	EPS (ttm)	4.38	Insider Own	1.10%	Shs Outstand	117.62M	Perf Week	2.63%
Market Cap	8.99B	Forward P/E	9.65	EPS next Y	7.97	Insider Trans	-17.29%	Shs Float	115.68M	Perf Month	18.07%
Enterprise Value	9.96B	PEG	0.54	EPS next Q	1.63	Inst Own	100.67%	Short Float	10.27%	Perf Quarter	41.00%
Income	557.28M	P/S	7.63	EPS this Y	45.74%	Inst Trans	-4.35%	Short Ratio	5.41	Perf Half Y	25.94%
Sales	1.18B	P/B	27.18	EPS next Y	29.21%	ROA	27.70%	Short Interest	11.88M	Perf YTD	60.85%
Book/sh	2.83	P/C	16.41	EPS next 5Y	32.26%	ROE	179.14%	52W High	77.58 -0.88%	Perf Year	29.77%
Cash/sh	4.69	P/FCF	16.64	EPS past 3/5Y	7.74% -	ROIC	30.26%	52W Low	42.01 83.05%	Perf 3Y	95.13%
Dividend Est.	-	EV/EBITDA	13.02	Sales past 3/5Y	31.82% 38.95%	Gross Margin	78.17%	Volatility	2.16% 2.27%	Perf 5Y	177.62%
Dividend TTM	-	EV/Sales	8.45	EPS Y/Y TTM	71.10%	Oper. Margin	57.92%	ATR (14)	1.69	Perf 10Y	356.38%
Dividend Ex-Date	-	Quick Ratio	7.01	Sales Y/Y TTM	34.97%	Profit Margin	47.28%	RSI (14)	77.93	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.36	EPS Q/Q	84.34%	SMA20	5.08%	Beta	1.17	Target Price	70.56
Payout	0.00%	Debt/Eq	4.54	Sales Q/Q	40.79%	SMA50	18.81%	Rel Volume	0.51	Prev Close	77.53
Employees	350	LT Debt/Eq	4.54	Earnings	Aug 05 AMC	SMA200	32.52%	Avg Volume	2.20M	Price	76.90
IPO	Mar 12, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.76% 13.92%	Trades		Volume	1,120,990	Change	-0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48

Show Previous Ratings

Sep-09-25 09:55AM	5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts (Zacks)
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
09:42AM	Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion (Zacks)
Sep-05-25 10:17AM	Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings (Zacks)
09:08AM	Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns (Zacks)
10:51AM	Loading…
Sep-04-25 10:51AM	4 PEG-Rated GARP Stocks That Offer Both Value and Growth (Zacks)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
12:00PM	Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice (Zacks)
10:00AM	Best Momentum Stock to Buy for September 3rd (Zacks)
09:40AM	Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? (Zacks)
09:15AM	Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue? (Zacks)
09:00AM	How to Find Strong Buy Medical Stocks Using the Zacks Rank (Zacks)
06:23AM	New Strong Buy Stocks for September 3rd (Zacks)
Sep-02-25 08:30AM	Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today (Zacks)
Aug-29-25 04:52AM	Halozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand (Insider Monkey)
12:26AM	Loading…
12:26AM	Morgan Stanley Raises PT on Halozyme Therapeutics (HALO) to $80 From $75 (Insider Monkey)
Aug-28-25 11:50PM	Morgan Stanley Raises PT on Halozyme Therapeutics (HALO), After Q2 Results (Insider Monkey)
08:30AM	Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
Aug-26-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-25-25 08:58AM	Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance (Insider Monkey)
Aug-22-25 08:05AM	Biotech Leader Rallies To Highs As Funds Load Up (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-12-25 09:10AM	H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 (Insider Monkey)
Aug-11-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-08-25 09:55AM	After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright (Zacks)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Aug-06-25 11:57AM	HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
03:27AM	Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
07:00PM	Loading…
Aug-05-25 07:00PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
06:05PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS (PR Newswire)
Aug-04-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jul-30-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-29-25 10:00AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-28-25 02:07AM	Morgan Stanley Maintains a Hold on Halozyme Therapeutics (HALO) With a $62 PT (Insider Monkey)
Jul-23-25 11:36AM	European Commission Approved DARZALEX Faspro for Adult Patients with Smouldering Multiple Myeloma (PR Newswire)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jul-22-25 12:10PM	Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again (Zacks)
09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
08:50AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
08:30AM	Halozyme to Report Second Quarter 2025 Financial and Operating Results (PR Newswire)
Jul-16-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jul-04-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-03-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jun-30-25 04:05PM	Halozyme Therapeutics Added to Russell 1000 Index (PR Newswire)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Jun-20-25 01:15PM	Halozyme Announces argenx Received European Commission Approval for VYVGART Subcutaneous Injection with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Jun-17-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Jun-16-25 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
Jun-13-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-05-25 11:30AM	Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? (Zacks)
Jun-04-25 08:55AM	PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo (TipRanks)
08:50AM	Merck granted review of Halozyme patent claims by PTAB (TipRanks)
05:08AM	Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme (Zacks)
Jun-03-25 10:45AM	4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025 (Zacks)
May-29-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-28-25 04:05PM	Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks)
10:15AM	Implied Volatility Surging for Halozyme Therapeutics Stock Options (Zacks)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
08:30AM	Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo (nivolumab) Co-Formulated with ENHANZE Across Multiple Solid Tumor Indications (PR Newswire)
04:37AM	New Strong Buy Stocks for May 28th (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-23-25 10:01AM	Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases (Zacks)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
09:50AM	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks)
May-20-25 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +6.27%
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
05:41AM	Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
11:23AM	4 Stocks With Impressive Interest Coverage Ratio to Buy Now (Zacks)
11:00AM	Halozyme, J&J slide as analyst cuts rating on CMS draft guidance (TipRanks)
08:27AM	Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday (Insider Monkey)
May-13-25 04:18PM	Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News (Investor's Business Daily) -24.56%
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
May-12-25 03:49PM	Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now? (Insider Monkey)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) (Zacks)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-10-25 11:47AM	S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points (Investor's Business Daily)
May-09-25 12:00PM	Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? (Zacks)
10:36AM	Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-08-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
01:47AM	Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 12:13PM	HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View (Zacks) +18.12%
03:19AM	Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 07:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS (PR Newswire)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Option Exercise	12.11	12,406	150,217	44,306	Sep 11 05:09 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Sep 10 '25	Sale	75.71	20,000	1,514,267	24,306	Sep 11 05:09 PM
NICOLE LABROSSE	Officer	Sep 10 '25	Proposed Sale	76.07	22,227	1,690,808		Sep 10 04:37 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Option Exercise	8.11	20,000	162,200	753,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 03 '25	Sale	74.44	20,000	1,488,726	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 04 '25	Sale	74.04	20,000	1,480,772	733,719	Sep 04 05:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 02 '25	Sale	73.76	20,000	1,475,128	733,719	Sep 04 05:41 PM
Connaughton Bernadette	Director	Sep 02 '25	Sale	73.68	4,000	294,736	46,952	Sep 02 08:11 PM
BERNADETTE CONNAUGHTON	Director	Sep 02 '25	Proposed Sale	73.15	8,829	645,841		Sep 02 04:38 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Option Exercise	8.11	20,000	162,200	753,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '25	Sale	64.32	20,000	1,286,351	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 12 '25	Sale	63.51	20,000	1,270,121	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Aug 11 '25	Sale	63.05	20,000	1,260,917	733,719	Aug 13 06:22 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 10 '25	Sale	57.43	20,000	1,148,618	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 09 '25	Sale	56.43	20,000	1,128,655	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '25	Sale	55.51	20,000	1,110,245	733,719	Jul 10 07:43 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Option Exercise	8.11	20,000	162,200	753,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 24 '25	Sale	53.73	20,000	1,074,620	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 20 '25	Sale	52.96	20,000	1,059,200	733,719	Jun 24 05:40 PM
Torley Helen	PRESIDENT AND CEO	Jun 23 '25	Sale	52.57	20,000	1,051,460	733,719	Jun 24 05:40 PM
Helen Torley	President, CEO, Director	Jun 20 '25	Proposed Sale	53.15	240,000	12,756,000		Jun 20 04:25 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '25	Option Exercise	0.00	5,035	0	33,524	Jun 13 05:33 PM
Henderson Jeffrey William	Director	Apr 28 '25	Sale	60.37	4,497	271,467	28,611	Apr 28 06:04 PM
Henderson Jeffrey William	Director	Apr 01 '25	Sale	64.05	503	32,217	33,108	Apr 01 06:32 PM
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM
Henderson Jeffrey William	Director	Feb 03 '25	Sale	56.30	5,000	281,517	38,611	Feb 04 06:07 PM
JEFFREY HENDERSON	Director	Feb 03 '25	Proposed Sale	56.64	15,000	849,600		Feb 03 04:21 PM
Henderson Jeffrey William	Director	Jan 06 '25	Sale	50.01	10,000	500,060	43,611	Jan 07 04:14 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '25	Option Exercise	0.00	7,611	0	19,291	Jan 06 05:12 PM
JEFFREY HENDERSON	Director	Jan 06 '25	Proposed Sale	47.74	10,000	477,400		Jan 06 04:26 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Option Exercise	19.98	10,000	199,800	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Option Exercise	18.15	10,000	181,455	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Sale	53.75	10,000	537,469	173,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Sale	53.26	10,000	532,590	173,756	Oct 16 06:53 PM
MICHAEL LABARRE	Officer	Oct 16 '24	Proposed Sale	53.26	10,000	532,592		Oct 16 04:14 PM
MICHAEL LABARRE	Officer	Oct 15 '24	Proposed Sale	53.75	10,000	537,466		Oct 15 04:34 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Sale	54.00	10,000	539,961	676,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Sale	52.58	10,000	525,783	676,744	Oct 09 05:39 PM
HELEN TORLEY	Officer	Oct 09 '24	Proposed Sale	52.58	10,000	525,778		Oct 09 04:09 PM
HELEN TORLEY	Officer	Oct 08 '24	Proposed Sale	54.00	10,000	539,956		Oct 08 04:08 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Sale	58.21	10,000	582,100	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Sale	56.34	10,000	563,370	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Sale	56.10	10,000	560,970	676,744	Sep 26 06:06 PM
HELEN TORLEY	Officer	Sep 26 '24	Proposed Sale	56.10	10,000	560,970		Sep 26 04:05 PM
HELEN TORLEY	Officer	Sep 25 '24	Proposed Sale	56.34	10,000	563,368		Sep 25 04:00 PM
HELEN TORLEY	Officer	Sep 24 '24	Proposed Sale	58.21	10,000	582,101		Sep 24 04:05 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Sale	62.88	10,000	628,780	173,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Sale	62.03	10,000	620,316	173,756	Sep 18 06:49 PM
MICHAEL LABARRE	Officer	Sep 18 '24	Proposed Sale	62.03	10,000	620,311		Sep 18 04:01 PM
MICHAEL LABARRE	Officer	Sep 17 '24	Proposed Sale	62.88	10,000	628,777		Sep 17 04:03 PM

BDX Becton Dickinson & Co daily Stock Chart

Peers: JNJ ABT DHR BAX TMO ISRG HOLX BSX ALGN XRAY

| Held by: VTI VOO SPY IVV VO VTV XLV VIG SDY IHI

Index	S&P 500	P/E	33.60	EPS (ttm)	5.56	Insider Own	0.18%	Shs Outstand	286.63M	Perf Week	-2.88%
Market Cap	53.55B	Forward P/E	12.57	EPS next Y	14.87	Insider Trans	-0.35%	Shs Float	286.10M	Perf Month	-4.65%
Enterprise Value	72.08B	PEG	5.30	EPS next Q	3.92	Inst Own	92.00%	Short Float	1.59%	Perf Quarter	7.10%
Income	1.61B	P/S	2.50	EPS this Y	9.44%	Inst Trans	-0.41%	Short Ratio	1.72	Perf Half Y	-16.14%
Sales	21.39B	P/B	2.10	EPS next Y	3.37%	ROA	2.91%	Short Interest	4.56M	Perf YTD	-17.64%
Book/sh	88.87	P/C	65.39	EPS next 5Y	6.34%	ROE	6.26%	52W High	251.99 -25.85%	Perf Year	-20.73%
Cash/sh	2.86	P/FCF	21.00	EPS past 3/5Y	-5.10% 8.27%	ROIC	3.73%	52W Low	163.33 14.39%	Perf 3Y	-27.85%
Dividend Est.	4.04 (2.16%)	EV/EBITDA	13.60	Sales past 3/5Y	1.79% 4.47%	Gross Margin	45.08%	Volatility	1.64% 1.72%	Perf 5Y	-18.13%
Dividend TTM	4.16 (2.23%)	EV/Sales	3.37	EPS Y/Y TTM	14.24%	Oper. Margin	14.14%	ATR (14)	3.71	Perf 10Y	40.37%
Dividend Ex-Date	Sep 08, 2025	Quick Ratio	0.62	Sales Y/Y TTM	7.86%	Profit Margin	7.51%	RSI (14)	44.79	Recom	2.43
Dividend Gr. 3/5Y	4.60% 4.29%	Current Ratio	1.10	EPS Q/Q	19.11%	SMA20	-3.24%	Beta	0.27	Target Price	203.12
Payout	64.86%	Debt/Eq	0.76	Sales Q/Q	10.40%	SMA50	0.39%	Rel Volume	0.40	Prev Close	190.56
Employees	74000	LT Debt/Eq	0.69	Earnings	Aug 07 BMO	SMA200	-8.37%	Avg Volume	2.65M	Price	186.84
IPO	Sep 25, 1963	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.20% 0.41%	Trades		Volume	1,061,258	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
May-22-25	Downgrade	Citigroup	Buy → Neutral	$185
May-02-25	Downgrade	Raymond James	Outperform → Mkt Perform
May-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$185
May-02-25	Downgrade	Goldman	Buy → Neutral	$192
May-01-25	Downgrade	William Blair	Outperform → Mkt Perform
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-01-25	Downgrade	BofA Securities	Buy → Neutral	$190
Oct-01-24	Upgrade	Citigroup	Neutral → Buy	$255 → $275
May-30-24	Initiated	Goldman	Buy	$274
Jul-24-23	Upgrade	Raymond James	Mkt Perform → Outperform	$305
May-30-23	Resumed	Morgan Stanley	Overweight	$295
May-05-23	Upgrade	Piper Sandler	Neutral → Overweight	$260 → $290
Apr-12-23	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$304
Jan-03-23	Upgrade	BofA Securities	Neutral → Buy	$250 → $290
Dec-12-22	Upgrade	Citigroup	Sell → Neutral	$221 → $250
Jul-11-22	Downgrade	Citigroup	Neutral → Sell	$265 → $235
Jun-24-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$275
Mar-18-22	Resumed	Raymond James	Mkt Perform
Mar-02-22	Resumed	BofA Securities	Neutral	$290
Dec-08-21	Downgrade	Piper Sandler	Overweight → Neutral	$285 → $260

Show Previous Ratings

Sep-10-25 10:06AM	Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds (Zacks)
Sep-05-25 08:03AM	Is Becton, Dickinson and Company Stock Underperforming the S&P 500? (Barchart)
Sep-02-25 06:50AM	BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative (PR Newswire)
Aug-29-25 08:58AM	Becton, Dickinson and Company Generated Lower-Than-Expected Revenue in Q2 (Insider Monkey)
Aug-28-25 12:06PM	Are Options Traders Betting on a Big Move in Becton Dickinson Stock? (Zacks)
09:45AM	Loading…
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Aug-27-25 09:40AM	Here's Why Becton Dickinson (BDX) is a Strong Value Stock (Zacks)
06:46AM	Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy Here's Where He's Investing Instead (Benzinga)
Aug-19-25 07:24PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
Aug-18-25 12:18PM	Becton, Dickinson and Company Stock: Is Wall Street Bullish or Bearish? (Barchart)
Aug-17-25 11:34PM	Surgical Equipment & Consumables - Diversified Stocks Q2 Results: Benchmarking BD (NYSE:BDX) (StockStory)
Aug-14-25 04:15PM	BD to Present at Wells Fargo 2025 Healthcare Conference (PR Newswire)
10:00AM	ASEAN Infusion Pump Company Evaluation Report 2025 \| BD, Fresenius Kabi, and Terumo Lead with Innovations in Drug Delivery, Hospital Care, and Cardiovascular Solutions (GlobeNewswire)
01:35AM	5 Revealing Analyst Questions From BD's Q2 Earnings Call (StockStory)
Aug-12-25 12:30PM	[Latest] US Surgical Instrument Tracking Market Size/Share Worth USD 226.61 Million by 2034 at a 11.78% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
09:45AM	Loading…
09:45AM	Here's Why Becton Dickinson (BDX) is a Strong Growth Stock (Zacks)
03:22AM	BDX Q3 Deep Dive: Margin Expansion and Portfolio Moves Drive Positive Market Response (StockStory)
Aug-11-25 09:40AM	Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term (Zacks)
Aug-08-25 09:39AM	Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings? (Zacks)
09:27AM	Company News for Aug 8, 2025 (Zacks)
Aug-07-25 02:16PM	BD (NYSE:BDX) Reports Q2 In Line With Expectations, Stock Soars (StockStory) +8.86%
11:07AM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
11:02AM	BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q3 Earnings (Zacks)
07:40AM	Becton Dickinson (BDX) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
07:17AM	Becton Dickinson shares surge as Q3 earnings beat drives guidance hike (Investing.com)
06:41AM	Becton Dickinson: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	BD Reports Third Quarter Fiscal 2025 Financial Results (PR Newswire)
Aug-06-25 10:36PM	Becton, Dickinson and Company Submits Application to the FDA for a New, At-Home HPV Test (Insider Monkey)
05:20PM	Staar Surgical (STAA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:09AM	Loading…
08:09AM	Becton Dickinson (BDX) Fell Due to Decline in Organic Revenue Growth (Insider Monkey)
07:38AM	Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings? (Zacks)
Aug-05-25 11:09PM	What To Expect From BD's (BDX) Q2 Earnings (StockStory)
12:16PM	Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings? (Zacks)
08:02AM	Instylla Appoints MedTech Leader Sean Boyle as Chief Executive Officer (PR Newswire)
07:07AM	BD announces $35m investment to expand prefilled syringe manufacturing in US (Medical Device Network)
06:50AM	BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories (PR Newswire)
Aug-04-25 09:15AM	Curious about Becton Dickinson (BDX) Q3 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
06:55AM	BD submits application to FDA for at-home HPV test (Medical Device Network)
06:50AM	BD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care (PR Newswire)
Jul-31-25 04:15PM	BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening Self-Collected At Home (PR Newswire)
10:00AM	Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline (Zacks)
Jul-30-25 06:50AM	BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test (PR Newswire)
Jul-25-25 07:30AM	Earnings Preview: What to Expect From Becton, Dickinson and Company's Report (Barchart)
Jul-24-25 09:06AM	Hologic's International Momentum Takes Shape: Will Execution Pay Off? (Zacks)
06:43AM	BD announces wearable injector trial for subcutaneous delivery of biologics (Medical Device Network)
Jul-23-25 10:00AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
09:20AM	Becton, Dickinson and Company (BDX) Fell in Q2 as Earnings Fell Short of Expectations (Insider Monkey)
06:50AM	BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas Wearable Injector Technology for Biologic Drugs (PR Newswire)
Jul-22-25 04:15PM	BD Board Declares Dividend (PR Newswire)
Jul-20-25 04:05AM	The Smartest Dividend Stock to Buy With $1,000 Right Now (Motley Fool)
Jul-18-25 11:07AM	Vascular Access Devices Company Evaluation Report 2025 \| Becton Dickinson, Teleflex, and ICU Medical Strengthen Global Leadership Through Strategic Acquisitions and Product Innovation (GlobeNewswire)
04:41AM	Jim Cramer Notes Becton Dickinson Stock Recently "Finished in the Black" (Insider Monkey)
Jul-15-25 02:47PM	Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks (The Wall Street Journal)
10:25AM	Waters, BD Bioscience deal looks to be a good fit, says Stifel (TipRanks)
10:25AM	Waters deal adds variables to clean story, says Jefferies (TipRanks)
09:47AM	DoorDash, Southwest downgraded: Wall Street's top analyst calls (The Fly)
09:12AM	BD Partners With Waters to Build High-Volume Diagnostics Leader (Zacks)
08:29AM	Becton, Dickinson and Company (BDX) Traded Down on Weak Earnings (Insider Monkey)
06:56AM	BD Biosciences & Diagnostic Solutions and Waters to merge in $17.5bn deal (Medical Device Network)
Jul-14-25 11:35PM	Q1 Rundown: BD (NYSE:BDX) Vs Other Surgical Equipment & Consumables - Diversified Stocks (StockStory)
03:10PM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
01:15PM	Stock Market Today: Dow Flat As Nasdaq Ekes Out A Gain; This Rocket Stock Takes Off (Live Coverage) (Investor's Business Daily)
12:53PM	Stocks to Watch Monday: Tesla, Robinhood, Kenvue, Synopsys (The Wall Street Journal)
12:44PM	Top Stock Movers Now: Autodesk, Fortinet, Waters, and More (Investopedia)
11:14AM	Analytics Equipment Maker Waters Buys Becton Dickinson Unit in a $17.5B Deal (Investopedia)
11:06AM	Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit (Barrons.com)
11:05AM	Autodesk & PTC, Becton Dickson & Waters, crypto: Trending Tickers (Yahoo Finance Video)
10:31AM	Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal (The Wall Street Journal)
08:59AM	Here's Why Becton, Dickinson and Company (BDX) Traded Lower in Q2 (Insider Monkey)
07:48AM	Becton Dickinson gets its spinoff deal, but the stock is still falling (MarketWatch)
07:02AM	Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal (The Wall Street Journal)
07:02AM	Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal (The Wall Street Journal)
06:15AM	Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing (PR Newswire)
Jul-07-25 04:15PM	BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment (PR Newswire)
Jun-30-25 04:07PM	These Were the Best and Worst S&P 500 Stocks During the Second Quarter (Barrons.com)
Jun-26-25 02:55AM	BD's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Jun-25-25 06:34PM	Becton, Dickinson and Company (BDX): A Bull Case Theory (Insider Monkey)
09:13AM	Analyst Report: Becton, Dickinson and Company (Morningstar Research)
09:13AM	How Hologic Leverages Its Financial Firepower to Drive Long-Term Value (Zacks)
Jun-23-25 04:56PM	Top Stock Reports for Amazon.com, Home Depot & Cisco Systems (Zacks)
Jun-09-25 08:42AM	Hologic Climbs 13% in a Month: How Should You Play the Stock? (Zacks)
06:00AM	As tech leads, which stocks have outperformed since April 8 rout? (Yahoo Finance Video)
Jun-08-25 08:00AM	Here's How You Can Earn $100 In Passive Income By Investing In Becton Dickinson Stock (Benzinga)
Jun-04-25 11:30AM	Henry Schein (HSIC) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks)
08:41AM	Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact? (Zacks)
12:36AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Jun-03-25 11:14AM	SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now? (Zacks)
May-30-25 10:14AM	BD Stock Might See Short-term Decline After Warning on Tamponade Tubes (Zacks)
May-29-25 05:10AM	BD to launch registry study of atherectomy system for PAD treatment (Medical Device Network)
May-28-25 06:50AM	BD to Initiate Real-World Patient Data Registry for the Rotarex Atherectomy System in Treatment of Peripheral Artery Disease (PR Newswire)
May-27-25 04:15PM	BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference (PR Newswire)
May-21-25 06:38AM	Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' (PR Newswire)
May-19-25 10:12AM	BD Stock May Rise Following the Launch of FACSDiscover A8 Platform (Zacks)
May-13-25 07:07AM	BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies (PR Newswire)
May-12-25 05:02PM	First Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co (GuruFocus.com)
09:00AM	BD to Announce Financial Results for its Third Quarter of Fiscal 2025 (PR Newswire)
08:44AM	Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock? (Zacks)
May-09-25 12:39AM	3 Profitable Stocks with Questionable Fundamentals (StockStory)
May-07-25 01:28PM	Jim Cramer on Becton, Dickinson and Company (BDX): "A Shocking Miss for This Once-Reliable Med Tech Giant" (Insider Monkey)

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fraser Claire	Director	Sep 10 '25	Sale	187.50	917	171,938	22,226	Sep 11 12:36 PM
Fraser Claire	Director	Sep 10 '25	Proposed Sale	187.42	917	171,862		Sep 10 03:42 PM
Feld Michael	EVP & President, Life Sciences	Aug 22 '25	Sale	197.99	57	11,285	8,360	Aug 26 03:41 PM
MICHAEL FELD	Officer	Aug 22 '25	Proposed Sale	196.63	57	11,208		Aug 22 04:38 PM
HAYES GREGORY	Director	Aug 11 '25	Buy	191.57	5,250	1,005,742	6,046	Aug 11 04:15 PM
Fraser Claire	Director	Aug 08 '25	Sale	192.30	863	165,955	23,143	Aug 08 06:56 PM
Fraser Claire	Director	Aug 08 '25	Proposed Sale	192.21	863	165,880		Aug 08 02:32 PM
Garrison Michael David	EVP & President, Medical	Jul 18 '25	Option Exercise	147.68	6,360	939,245	11,247	Jul 22 05:29 PM
Garrison Michael David	EVP & President, Medical	Jul 18 '25	Sale	180.29	1,185	213,645	4,887	Jul 22 05:29 PM
MICHAEL GARRISON	Officer	Jul 18 '25	Proposed Sale	180.90	1,185	214,366		Jul 18 04:48 PM
Shan David	EVP and Chief ISC Officer	Jun 02 '25	Sale	171.19	1,166	199,608	4,575	Jun 02 06:44 PM
DAVID SHAN	Officer	Jun 02 '25	Proposed Sale	172.59	1,166	201,240		Jun 02 04:24 PM
Garrison Michael David	EVP & President, Medical	Apr 09 '25	Sale	197.28	479	94,497	4,887	Apr 10 01:56 PM
MICHAEL GARRISON	Officer	Apr 09 '25	Proposed Sale	200.83	479	96,198		Apr 09 04:16 PM
Byrd Richard	EVP & President Interventional	Mar 18 '25	Sale	230.00	459	105,570	6,952	Mar 19 01:55 PM
RICHARD BYRD	Officer	Mar 18 '25	Proposed Sale	227.83	459	104,574		Mar 18 04:33 PM
Byrd Richard	EVP & President Interventional	Mar 12 '25	Sale	224.91	1,940	436,325	7,411	Mar 13 01:03 PM
RICHARD BYRD	Officer	Mar 12 '25	Proposed Sale	224.92	1,940	436,345		Mar 12 04:22 PM
SCOTT BERTRAM L	Director	Feb 12 '25	Sale	227.99	700	159,593	36,033	Feb 12 04:44 PM
BERTRAM SCOTT	Director	Feb 12 '25	Proposed Sale	227.99	700	159,593		Feb 12 04:12 PM
Henderson Jeffrey William	Director	Feb 10 '25	Buy	233.62	1,500	350,430	8,015	Feb 10 05:03 PM
Shan David	EVP and Chief ISC Officer	Jan 21 '25	Sale	240.00	500	120,000	5,741	Jan 22 09:19 AM
Neal Shana Carol	EVP and Chief People Officer	Jan 21 '25	Sale	240.00	787	188,880	15,414	Jan 22 09:18 AM
SHANA NEAL	Officer	Jan 21 '25	Proposed Sale	237.38	787	186,818		Jan 21 04:21 PM
DAVID SHAN	Officer	Jan 21 '25	Proposed Sale	237.38	500	118,690		Jan 21 01:47 PM
Garrison Michael David	EVP & President, Medical	Jan 17 '25	Sale	236.51	597	141,196	5,544	Jan 21 08:21 AM
MICHAEL GARRISON	Officer	Jan 17 '25	Proposed Sale	236.30	597	141,071		Jan 17 04:20 PM
Neal Shana Carol	EVP and Chief People Officer	Nov 21 '24	Option Exercise	0.00	111	0	17,021	Jan 10 07:11 AM
Neal Shana Carol	EVP and Chief People Officer	Jan 07 '25	Sale	235.00	788	185,180	16,201	Jan 10 07:11 AM
SHANA NEAL	Officer	Jan 07 '25	Proposed Sale	230.70	788	181,792		Jan 07 04:19 PM
Garrison Michael David	EVP & President, Medical	Dec 19 '24	Sale	223.33	2,838	633,811	6,141	Dec 20 10:18 AM
MICHAEL GARRISON	Officer	Dec 19 '24	Proposed Sale	224.09	2,838	635,967		Dec 19 04:20 PM
Goette Roland	EVP and President, EMEA	Dec 06 '24	Option Exercise	157.30	13,334	2,097,403	28,828	Dec 10 08:23 PM
Goette Roland	EVP and President, EMEA	Dec 06 '24	Sale	221.01	4,483	990,788	24,345	Dec 10 08:23 PM
Goette Roland	EVP and President, EMEA	Dec 09 '24	Sale	219.03	638	139,741	14,217	Dec 10 08:23 PM
Neal Shana Carol	EVP and Chief People Officer	Dec 06 '24	Sale	220.49	1,000	220,490	16,989	Dec 10 08:17 PM
ROLAND GOETTE	Officer	Dec 09 '24	Proposed Sale	220.02	638	140,373		Dec 09 04:47 PM
Shan David	EVP and Chief ISC Officer	Dec 05 '24	Sale	220.25	1,500	330,375	6,285	Dec 06 04:55 PM
ROLAND GOETTE	Officer	Dec 06 '24	Proposed Sale	222.24	4,483	996,302		Dec 06 04:31 PM
SHANA NEAL	Officer	Dec 06 '24	Proposed Sale	222.24	1,000	222,240		Dec 06 04:31 PM
DAVID SHAN	Officer	Dec 05 '24	Proposed Sale	221.43	1,500	332,145		Dec 05 04:42 PM
BURZIK CATHERINE M	Director	Sep 16 '24	Proposed Sale	235.78	400	94,312		Sep 16 11:52 AM

HALO

Halozyme Therapeutics Inc

BDX

Becton Dickinson & Co

Upgrade your FINVIZ experience